CD59 Recombinant Rabbit monoclonal Antibody IgG
Fig1: Western blot analysis of CD59 on different cells lysates using anti-CD59 antibody at 1/500 dilution.
Lane 1: Human placenta
Lane 2: HUVEC
Lane 3: K562
Fig2: ICC staining CD59 in HUVEC cells (red). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Fig3: ICC staining CD59 in JAR cells (red). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Host Species; Species ReactivityRabbit; Human
Application SummaryWB, ICC/IF, FC,IP
Purification; FormulationProA affinity purified; 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide.; Liquid form.
ALTnamesCD59 glycoprotein, 1F5 antigen, 20 kDa homologous restriction factor, MAC-inhibitory protein, MEM43 antigen, Membrane attack complex inhibition factor, Membrane inhibitor of reactive lysis, Protectin
BackgroundCD59 is a GPI-anchored glycoprotein that is expressed on leukocytes, vascular endothelial cells, various epithelial cells and placenta. CD59 acts together with CD58 in mediating T cell adhesion and activation, and it may be a second ligand of CD2. CD59 functions as a regulator of the terminal pathway of complement by binding to the C8/C9 components of the assembling membrane attack complex (MAC) on host cell membranes, to stop the formation of the lytic pore. CD59 also drives both calcium release and activation of lipid-raft associated signalling molecules such as tyrosine kinases. CD59 gene has two p53-responsive domains that may be implicated in the defense of host cells from damage by the complement system in inflammation, suggesting that p53 could be used to mediate susceptibility of tumor cells to the complement lysis during chemotherapy.(ET1703-28)